All In Biotech

Drug Trial Radar · NCT04159519

A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

SHAMAL: A Multicentre, Randomised, Open-Label, Parallel-Group, Active-Controlled, Phase IV Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab

Last checked: Nov 20, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

170

Actual

Start

Jul 27, 2020

Primary completion

Jan 31, 2023

Study completion Jan 31, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicentre, randomised, open-label, parallel-group, active-controlled, phase IV study to assess the reduction of daily Symbicort® maintenance to anti-inflammatory reliever treatment only in participants with severe eosinophilic asthma on Fasenra® treatment, while maintaining asthma control.

Conditions

  • Asthma
  • Severe Eosinophilic Asthma

Interventions

  • Symbicort®Drug

    Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation or Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.

  • Fasenra®Drug

    Participants will receive Benralizumab 30 mg/mL, 1 mL fill volume via subcutaneous injection every 4 weeks for first 3 doses (prior to study inclusion), every 8 weeks thereafter.

  • Ventolin®Drug

    Participants will receive Salbutamol sulfate 100 μg per inhalation as needed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction PeriodTime frame: At Week 32

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Brest, France

  • Research Site

    Dijon, France

  • Research Site

    Le Kremlin-Bicêtre, France

  • Research Site

    Lille, France

  • Research Site

    Lyon, France

  • Research Site

    Pessac, France

  • Research Site

    Berlin, Germany

  • Research Site

    Bonn, Germany

  • Research Site

    Cottbus, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Jena, Germany

  • Research Site

    Mainz, Germany

  • Research Site

    Marburg, Germany

  • Research Site

    München, Germany

  • Research Site

    Bergamo, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Belfast, United Kingdom

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.